DMWD

DMWD (originally DMR-N9/gene59) is a WD-repeat-containing protein expressed predominantly in brain and testis that functions as an activating cofactor for the USP12/USP46 deubiquitinases and contributes to the congenital phenotypes of myotonic dystrophy type 1 (DM1) (PMID:7633444, PMID:33844468, PMID:31853004). The protein localizes in a punctate pattern throughout the neuronal cell body, nucleus, and dendrites/synapses while being excluded from axons, and is most prominent in synapse-dense neuropil (PMID:12691844). Mechanistically, DMWD directly binds USP12 and USP46 and stimulates their deubiquitinase activity; it engages the same interface on USP12 as its paralog WDR20, implying mutually exclusive binding, and the two cofactors differentially direct USP12 to distinct subcellular locations and therefore distinct substrate pools (PMID:33844468). DMWD lies immediately upstream of the DM-protein kinase gene, and in DM1 patient cells the CTG repeat-expanded allele shows allele-specific post-transcriptional reduction of DMWD mRNA confined to the cytoplasmic fraction (PMID:1302022, PMID:10400997); mouse genetic epistasis establishes that reduced Dmwd dosage specifically contributes to congenital DM1 manifestations (PMID:31853004). DMWD protein levels are post-transcriptionally upregulated during postnatal brain development independent of mRNA changes (PMID:12691844).

1. 1992 Medium

   Established DMWD as a discrete transcribed gene immediately upstream of the DM-kinase locus, distinguishing it from neighboring DM1 genes and defining its brain/testis expression—a prerequisite for asking whether it independently contributes to disease.

   Evidence cDNA characterization, Northern blotting and genomic mapping at the DM1 locus

   PMID:1302022

   Open questions at the time

   • No protein function assigned
   • Open reading frame product uncharacterized
2. 1995 Medium

   Identified two WD-repeat domains in the protein, placing DMWD in a family implicated in signal transduction/cell regulation and providing the first structural clue to its molecular role, alongside defining its developmental and cell-type expression.

   Evidence Genomic cloning, sequence analysis, Northern blotting and RNA in situ hybridization in mouse

   PMID:7633444

   Open questions at the time

   • WD-repeat domain assignment did not identify binding partners
   • No biochemical activity demonstrated
3. 1999 Medium

   Showed that the CTG repeat expansion acts in cis to reduce DMWD mRNA specifically in the cytoplasm of patient cells, providing a mechanism by which DM1 lowers DMWD expression beyond the kinase gene.

   Evidence Allele-specific quantitative RT-PCR on nuclear and cytoplasmic RNA fractions from DM patient cell lines

   PMID:10400997

   Open questions at the time

   • Mechanism of the cytoplasmic-specific reduction not defined
   • Functional consequence of reduced DMWD not tested here
4. 2003 Medium

   Defined DMWD's subcellular distribution to neuronal cell body, nucleus and dendrites/synapses (excluded from axons) and demonstrated post-transcriptional upregulation of protein during brain development, linking it to synaptic compartments.

   Evidence Western blotting, immunohistochemistry, subcellular fractionation and in vitro neuronal differentiation

   PMID:12691844

   Open questions at the time

   • No molecular partners identified at synapses
   • Functional role at dendrites/synapses not established
5. 2019 Medium

   Demonstrated by in vivo genetic epistasis that reduced Dmwd dosage contributes specifically to congenital (not adult-onset) DM1 features, establishing DMWD as a causal contributor to the disease phenotype rather than a bystander gene.

   Evidence Multigene heterozygous mouse models with behavioral/physiological phenotyping

   PMID:31853004

   Open questions at the time

   • Molecular pathway through which Dmwd dosage acts not defined
   • Cell type responsible for congenital phenotype not resolved
6. 2021 Medium

   Identified the first direct biochemical function of DMWD: it binds and activates USP12/USP46 deubiquitinases through the same interface as paralog WDR20 and differentially controls their subcellular localization, defining DMWD as a deubiquitinase-activating cofactor.

   Evidence Co-immunoprecipitation of tagged proteins, deubiquitinase activity assays, subcellular localization and phylogenetic analysis

   PMID:33844468

   Open questions at the time

   • Substrates directed by DMWD-bound USP12 not identified
   • Mutual exclusivity with WDR20 inferred, not directly shown
   • Link between DUB activation and DM1/neuronal phenotypes untested
7. 2025 Low

   Placed the DMWD ortholog in a pathway relevant to neuronal survival by showing its perturbation modulates neurodegeneration and that correcting its misexpression is neuroprotective in fly AD models.

   Evidence Drosophila transgenic AD models (tau and Aβ42) with genetic perturbation and behavioral readout

   PMID:40215969

   Open questions at the time

   • No direct molecular mechanism for DMWD identified
   • Single fly-model perturbation; relevance to mammalian DMWD unconfirmed
   • Connection to USP12/46 activity not tested

• How DMWD-directed USP12/USP46 deubiquitination connects to its synaptic localization and to congenital DM1 phenotypes remains unresolved.
• No substrate of DMWD-activated DUB identified
• No mechanistic bridge between cofactor activity and neuronal/disease phenotype